Enzyme‐MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy Academic Article uri icon

abstract

  • Prodrug activation, by exogenously administered enzymes, for cancer therapy is an approach to achieve better selectivity and less systemic toxicity than conventional chemotherapy. However, the short half-lives of the activating enzymes in the bloodstream has limited its success. Demonstrated here is that a tyrosinase-MOF nanoreactor activates the prodrug paracetamol in cancer cells in a long-lasting manner. By generating reactive oxygen species (ROS) and depleting glutathione (GSH), the product of the enzymatic conversion of paracetamol is toxic to drug-resistant cancer cells. Tyrosinase-MOF nanoreactors cause significant cell death in the presence of paracetamol for up to three days after being internalized by cells, while free enzymes totally lose activity in a few hours. Thus, enzyme-MOF nanocomposites are envisioned to be novel persistent platforms for various biomedical applications.

altmetric score

  • 10.35

author list (cited authors)

  • Lian, X., Huang, Y., Zhu, Y., Fang, Y. u., Zhao, R., Joseph, E., ... Zhou, H.

citation count

  • 98

publication date

  • April 2018

publisher